|
1
|
Munkholm P: Review article: The incidence
and prevalence of colorectal cancer in inflammatory bowel disease.
Aliment Pharmacol Ther. 18:(Suppl 2). 1–5. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheng Y and Desreumaux P: 5-aminosalicylic
acid is an attractive candidate agent for chemoprevention of colon
cancer in patients with inflammatory bowel disease. World J
Gastroenterol. 11:309–314. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Debril MB, Renaud JP, Fajas L and Auwerx
J: The pleiotropic functions of peroxisome proliferator-activated
receptor gamma. J Mol Med Berl. 79:30–47. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hontecillas R and Bassaganya-Riera J:
Peroxisome proliferator-activated receptor gamma is required for
regulatory CD4+ T cell-mediated protection against colitis. J
Immunol. 178:2940–2949. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schwab M, Reynders V, Loitsch S, Shastri
YM, Steinhilber D, Schröder O and Stein J: PPARgamma is involved in
mesalazine-mediated induction of apoptosis and inhibition of cell
growth in colon cancer cells. Carcinogenesis. 29:1407–1414. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Staa TP, Card T, Logan RF and Leufkens
HG: 5-Aminosalicylate use and colorectal cancer risk in
inflammatory bowel disease: A large epidemiological study. Gut.
54:1573–1578. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rousseaux C, Lefebvre B, Dubuquoy L,
Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B,
Naccari GC, et al: Intestinal antiinflammatory effect of
5-aminosalicylic acid is dependent on peroxisome
proliferator-activated receptor-gamma. J Exp Med. 201:1205–1215.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koelink PJ, Mieremet-Ooms MA, Corver WE,
Wolanin K, Hommes DW, Lamers CB and Verspaget HW: 5-aminosalicylic
acid interferes in the cell cycle of colorectal cancer cells and
induces cell death modes. Inflamm Bowel Dis. 16:379–389. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kohno H, Suzuki R, Sugie S and Tanaka T:
Suppression of colitis-related mouse colon carcinogenesis by a
COX-2 inhibitor and PPAR ligands. BMC Cancer. 5:462005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cooper HS, Murthy SN, Shah RS and
Sedergran DJ: Clinicopathologic study of dextran sulfate sodium
experimental murine colitis. Lab Invest. 69:238–249.
1993.PubMed/NCBI
|
|
11
|
Ni J, Chen SF and Hollander D: Effects of
dextran sulphate sodium on intestinal epithelial cells and
intestinal lymphocytes. Gut. 39:234–241. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cooper HS, Everley L, Chang WC, Pfeiffer
G, Lee B, Murthy S and Clapper ML: The role of mutant Apc in the
development of dysplasia and cancer in the mouse model of dextran
sulfate sodium-induced colitis. Gastroenterology. 121:1407–1416.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tanaka T, Kohno H, Suzuki R, Hata K, Sugie
S, Niho N, Sakano K, Takahashi M and Wakabayashi K: Dextran sodium
sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+)
mice: Inflammatory stimuli by dextran sodium sulfate results in
development of multiple colonic neoplasms. Int J Cancer. 118:25–34.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Murano M, Maemura K, Hirata I, Toshina K,
Nishikawa T, Hamamoto N, Sasaki S, Saitoh O and Katsu K:
Therapeutic effect of intracolonically administered nuclear factor
kappa B (p65) antisense oligonucleotide on mouse dextran sulphate
sodium (DSS)-induced colitis. Clin Exp Immunol. 120:51–58. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Onderdonk AB and Bartlett JG:
Bacteriological studies of experimental ulcerative colitis. Am J
Clin Nutr. 32:258–265. 1979.PubMed/NCBI
|
|
16
|
Jin Z, Jiang W, Jiao F, Hu H, Guo Z and
Wang L and Wang L: Decreased expression of histone deacetylase 10
predicts poor prognosis of gastric cancer patients. Int J Clin Exp
Pathol. 7:5872–5879. 2014.PubMed/NCBI
|
|
17
|
Dubuquoy L, Dharancy S, Nutten S,
Pettersson S, Auwerx J and Desreumaux P: Role of peroxisome
proliferator-activated receptor gamma and retinoid X receptor
heterodimer in hepatogastroenterological diseases. Lancet.
360:1410–1418. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dubuquoy L, Rousseaux C, Thuru X,
Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M and
Desreumaux P: PPARgamma as a new therapeutic target in inflammatory
bowel diseases. Gut. 55:1341–1349. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grommes C, Landreth GE and Heneka MT:
Antineoplastic effects of peroxisome proliferator-activated
receptor gamma agonists. Lancet Oncol. 5:419–429. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen CW, Chang YH, Tsi CJ and Lin WW:
Inhibition of IFN-gamma-mediated inducible nitric oxide synthase
induction by the peroxisome proliferator-activated receptor gamma
agonist, 15-deoxy-delta 12,14-prostaglandin J2, involves inhibition
of the upstream Janus kinase/STAT1 signaling pathway. J Immunol.
171:979–988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sánchez-Hidalgo M, Martín AR, Villegas I
and Alarcón De La Lastra C: Rosiglitazone, an agonist of peroxisome
proliferator-activated receptor gamma, reduces chronic colonic
inflammation in rats. Biochem Pharmacol. 69:1733–1744. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang XY, Wang LH, Chen T, Hodge DR, Resau
JH, DaSilva L and Farrar WL: Activation of human T lymphocytes is
inhibited by peroxisome proliferator-activated receptor gamma
(PPARgamma) agonists. PPARgamma co-association with transcription
factor NFAT. J Biol Chem. 275:4541–4544. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Krishnan A, Nair SA and Pillai MR: Biology
of PPAR gamma in cancer: A critical review on existing lacunae.
Curr Mol Med. 7:532–540. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hontecillas R, Horne WT, Climent M, Guri
AJ, Evans C, Zhang Y, Sobral BW and Bassaganya-Riera J:
Immunoregulatory mechanisms of macrophage PPAR-γ in mice with
experimental inflammatory bowel disease. Mucosal Immunol.
4:304–313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamamoto-Furusho JK, Peñaloza-Coronel A,
Sánchez-Muñoz F, Barreto-Zuñiga R and Dominguez-Lopez A: Peroxisome
proliferator-activated receptor-gamma (PPAR-γ) expression is
downregulated in patients with active ulcerative colitis. Inflamm
Bowel Dis. 17:680–681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Farrell RJ and Peppercorn MA: Ulcerative
colitis. Lancet. 359:331–340. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ikeda I, Tomimoto A, Wada K, Fujisawa T,
Fujita K, Yonemitsu K, Nozaki Y, Endo H, Takahashi H, Yoneda M, et
al: 5-aminosalicylic acid given in the remission stage of colitis
suppresses colitis-associated cancer in a mouse colitis model. Clin
Cancer Res. 13:6527–6531. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Koelink PJ, Robanus-Maandag EC, Devilee P,
Hommes DW, Lamers CB and Verspaget HW: 5-Aminosalicylic acid
inhibits colitis-associated but not sporadic colorectal neoplasia
in a novel conditional Apc mouse model. Carcinogenesis.
30:1217–1224. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Riddell RH, Goldman H, Ransohoff DF,
Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton
SR, Morson BC, et al: Dysplasia in inflammatory bowel disease:
Standardized classification with provisional clinical applications.
Hum Pathol. 14:931–968. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Clapper ML, Gary MA, Coudry RA, Litwin S,
Chang WC, Devarajan K, Lubet RA and Cooper HS: 5-aminosalicylic
acid inhibits colitis-associated colorectal dysplasias in the mouse
model of azoxymethane/dextran sulfate sodium-induced colitis.
Inflamm Bowel Dis. 14:1341–1347. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Saif MW and Chu E: Biology of colorectal
cancer. Cancer J. 16:196–201. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu J and Farmer SR: Regulating the
balance between peroxisome proliferator-activated receptor gamma
and beta-catenin signaling during adipogenesis. A glycogen synthase
kinase 3beta phosphorylation-defective mutant of beta-catenin
inhibits expression of a subset of adipogenic genes. J Biol Chem.
279:45020–45027. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Atug O, Tahan V, Eren F, Tiftikci A,
Imeryuz N, Hamzaoglu HO and Tozun N: Pro12Ala polymorphism in the
peroxisome proliferator-activated receptor-gamma (PPARgamma) gene
in inflammatory bowel disease. J Gastrointestin Liver Dis.
17:433–437. 2008.PubMed/NCBI
|
|
34
|
Shrestha UK, Karimi O, Crusius JB, Zhou F,
Wang Z, Chen Z, van Bodegraven AA, Xiao J, Morré SA, Wang H, et al:
Distribution of peroxisome proliferator-activated receptor-gamma
polymorphisms in Chinese and Dutch patients with inflammatory bowel
disease. Inflamm Bowel Dis. 16:312–319. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jennewein C, von Knethen A, Schmid T and
Brüne B: MicroRNA-27b contributes to lipopolysaccharide-mediated
peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA
destabilization. J Biol Chem. 285:11846–11853. 2010. View Article : Google Scholar : PubMed/NCBI
|
